Trials Sponsors Conditions Drugs Pricing

Conditions

Immune Thrombocytopenia

Keywords

Immune Thrombocytopeniamacrophagespleen tissue

Outcome Measures

Primary Outcomes (3)

Evaluation of platelet response (Complete Response)
CR. A complete response (CR) was defined as a sustained (≥ 3 months) platelet count ≥ 100×10\^9/L without recurrence of thrombocytopenia
The time frame is up to 3 months per subject
Evaluation of platelet response (R)
R. A response (R) was defined as a sustained (≥ 3 months) platelet count ≥ 30×10\^9/L without recurrence of thrombocytopenia
The time frame is up to 3 months per subject
Evaluation of platelet response (No Response)
NR.No response (NR) was defined as platelet count \< 30 × 10\^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart.
The time frame is up to 3 months per subject

Secondary Outcomes (1)

Macrophage Function
two weeks

Study Arms (2)

ITP patients accepted splenectomy

Trauma with spleen rupture underwent splenectomy

Eligibility Criteria

Age15 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Chinese Adult with primary immune thrombocytopenia

You may qualify if:

adult ITP patients whose platelet counts remain less than 10 x 10\^9/L

Sponsors & Collaborators

Shandong University
Otherlead

Study Sites (1)

Qilu Hospital, Shandong University

Jinan, Shandong, 250012, China

Biospecimen

Retention: SAMPLES WITH DNA

The biospecimens were retained for PCR, western blotting and FACS analysis.

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic

Condition Hierarchy (Ancestors)

Purpura, ThrombocytopenicPurpuraBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesThrombotic MicroangiopathiesThrombocytopeniaBlood Platelet DisordersCytopeniaHemorrhagic DisordersAutoimmune DiseasesImmune System DiseasesHemorrhagePathologic Processes

Study Officials

Jun Peng, dr.
Qilu Hospital of Shandong University
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: professor

Study Record Dates

First Submitted

April 3, 2013

First Posted

June 5, 2013

Study Start

November 2012

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (2)

ITP patients accepted splenectomy

Trauma with spleen rupture underwent splenectomy

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (2)

ITP patients accepted splenectomy

Trauma with spleen rupture underwent splenectomy

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations